前往化源商城

inosine 5'-(trihydrogen diphosphate)

更新时间:2024-01-03 18:37:21

inosine 5'-(trihydrogen diphosphate)结构式
inosine 5'-(trihydrogen diphosphate)结构式
品牌特惠专场
常用名 inosine 5'-(trihydrogen diphosphate) 英文名 inosine 5'-(trihydrogen diphosphate)
CAS号 86-04-4 分子量 522.14900
密度 2.49g/cm3 沸点 925.2ºC at 760 mmHg
分子式 C10H13N4O15P3-- 熔点 N/A
MSDS N/A 闪点 513.3ºC

 用途


核糖(IDP)是一种口服活性嘌呤衍生物次黄嘌呤rlboside,具有抗缺氧和抗高血压活性。在由哇巴因引起的心律失常的猫、兔和小鼠中,核糖也具有抗心律失常作用。Riboxin保护动物免受γ辐射的伤害[1][2]。

 inosine 5'-(trihydrogen diphosphate)名称

英文名 idp
英文别名 更多

 inosine 5'-(trihydrogen diphosphate)生物活性

描述 核糖(IDP)是一种口服活性嘌呤衍生物次黄嘌呤rlboside,具有抗缺氧和抗高血压活性。在由哇巴因引起的心律失常的猫、兔和小鼠中,核糖也具有抗心律失常作用。Riboxin保护动物免受γ辐射的伤害[1][2]。
相关类别
体内研究 Riboxin(250 mg/kg;口服; 单剂量) 可增加小鼠的游泳时间,但对力量耐力无显著影响。在相同条件下,核糖核酸提高了热室实验中动物的存活率[1]。 Riboxin(50 mg/kg;口服; 每天1.次,持续6.天) 增加小鼠游走的时间,而对游泳和跑步的时间无显著影响[1]。 Riboxin(250 mg/kg;口服; 实验前 1.小时) 对小鼠有明显的 γ 辐照保护作用[1]。
参考文献

[1]. Sokolov I K, et al. Adaptogenic effect of riboxin[J]. Pharmaceutical Chemistry Journal, 1980, 14(1): 34-39.

[2]. Veveris M, et al. Experimental study of the antiarrhythmic effect of riboxin. Farmakol. Neirotropnykh Sredstv (1978), 119-24.

 inosine 5'-(trihydrogen diphosphate)物理化学性质

密度 2.49g/cm3
沸点 925.2ºC at 760 mmHg
分子式 C10H13N4O15P3--
分子量 522.14900
闪点 513.3ºC
精确质量 521.95900
PSA 328.66000
折射率 1.883

 inosine 5'-(trihydrogen diphosphate)毒性和生态

 inosine 5'-(trihydrogen diphosphate)英文别名

O5'-trihydroxydiphosphoryl-inosine
riboxine
Inosindiphosphat
Inosine 5'-pyrophosphate
Inosin-5'-diphosphat
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-3H-purin-9-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
Inosine diphosphate
Inosine 5'-diphosphate
5'-inosine diphosphate
Riboxin
品牌现货直购
推荐供应商:

暂无推荐供应商。我要出现这里

相关化合物: 更多...
2'-Deoxyinosine 5'-(trihydrogen diphosphate)
26575-15-5
1-beta-D-Ribofuranosylinosine 5'-(trihydrogen diphosphate) intramol. P',5''-ester
856702-89-1
Inosine-5'-diphosphate trisodium salt
81012-88-6
Cytidine 5'-(trihydrogen diphosphate), mono[2-(trimethylammonio)ethyl] ester
1256-10-6
guanosine 5'-(trihydrogen diphosphate)-N-(4-azidophenyl)-2-phosphoramido-3-(4-hydroxy-3-iodophenyl)propionamide monoanhydride
129592-79-6
Guanosine 5'-(trihydrogen diphosphate), 2'-deoxy-, disodium salt
78101-74-3
Cytidine 5'-(trihydrogen diphosphate), 2'-O-methyl-, tripotassium salt
93839-94-2
Cytidine 5'-(trihydrogen diphosphate), compd. with 2-aminoethanol (1:1), monosodium salt
93980-55-3
Adenosine 5'-(trihydrogen diphosphate), potassium salt
35170-30-0
4-[({1-[(tert-butoxy)carbonyl]-3-methylpiperidin-4-yl}methyl)({[(9H-fluoren-9-yl)methoxy]carbonyl})amino]butanoic acid
2138546-87-7
4-{[2-(4-{[(tert-butoxy)carbonyl]amino}oxan-4-yl)ethyl]({[(9H-fluoren-9-yl)methoxy]carbonyl})amino}butanoic acid
2138120-76-8
4-{[(4-{[(tert-butoxy)carbonyl]amino}-1-methyl-1H-pyrazol-5-yl)methyl]({[(9H-fluoren-9-yl)methoxy]carbonyl})amino}butanoic acid
2138586-04-4
5-methyl-1-[(3-methylcyclobutyl)methyl]-1H-pyrazole-4-carboxylic acid
2138109-76-7
1-[(3-methylcyclobutyl)methyl]-5-(propan-2-yl)-1H-pyrazole-4-carboxylic acid
2138104-67-1
4-{[(3-{[(tert-butoxy)carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-3-yl)methyl]({[(9H-fluoren-9-yl)methoxy]carbonyl})amino}butanoic acid
2138586-11-3
4-({[4-({[(tert-butoxy)carbonyl]amino}methyl)oxan-4-yl]methyl}({[(9H-fluoren-9-yl)methoxy]carbonyl})amino)butanoic acid
2138548-31-7
4-[(2-{[(tert-butoxy)carbonyl](methyl)amino}-2-methylpropyl)({[(9H-fluoren-9-yl)methoxy]carbonyl})amino]butanoic acid
2138098-82-3
rac-4-({[(1R,5R)-3-[(tert-butoxy)carbonyl]-5-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-1-yl]methyl}({[(9H-fluoren-9-yl)methoxy]carbonyl})amino)butanoic acid
2138090-93-2
2-(2-Methylpyrrolidin-1-yl)quinazoline-5-carboxylic acid
2138058-93-0